Equine Veterinary Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs (Anti-Inflammatory, Anti-Infective, Parasiticides, Others), By Route of Administration (Oral, Parental, Topical), By Distribution Channel (Veterinary Hospital, Veterinary Clinics, Pharmacies and drug stores, E-commerce, Other), By Region and Competition, 2020-2030F

Market Overview

The Global Equine Veterinary Therapeutics Market, valued at USD 1.82 Billion in 2024, is projected to experience a CAGR of 7.21% to reach USD 2.76 Billion by 2030. The Global Equine Veterinary Therapeutics Market encompasses pharmaceuticals, vaccines, and diagnostic tools specifically developed to maintain and restore the health of horses. This market's growth is primarily driven by the increasing prevalence of various equine diseases, a heightened awareness among horse owners regarding animal welfare and preventive care, and the sustained expansion of equestrian sports globally. According to the Fédération Équestre Internationale (FEI), as of 2025, 490,362 horses are actively entered in their database, with approximately 78,400 new registrations occurring each year, underscoring the substantial addressable market.

Further supporting this market are continuous advancements in veterinary medicine and increased investment in equine healthcare infrastructure. However, a significant challenge impeding market expansion is the persistent shortage of skilled equine veterinarians. The 2024 AVMA/AAEP Report on the Economic State of the Equine Veterinary Profession noted that in 2023, only 6.1% of veterinary graduates chose to enter equine practice, highlighting a critical labor supply constraint for delivering these essential therapeutics.

Key Market Drivers

Increased equine health awareness and the rising adoption of preventative care significantly drive the global equine veterinary therapeutics market. Horse owners are increasingly recognizing the long-term benefits of proactive health management, leading to greater demand for vaccines, parasiticides, and nutritional supplements. This shift towards preventative strategies minimizes the incidence and severity of diseases, thereby necessitating a steady supply of efficacious therapeutics for routine immunization and health maintenance. For instance, according to ResearchGate's 'Preventive health care and owner-reported disease prevalence of horses and ponies in Great Britain' study, in August 2025, 71.3% of horses and ponies in Great Britain were vaccinated for both influenza and tetanus, illustrating a high rate of preventative intervention. This focus on regular veterinary check-ups and adherence to vaccination schedules directly contributes to the sustained demand for a wide array of pharmaceutical products designed to preserve equine well-being.

Technological advancements in equine veterinary medicine represent another pivotal driver, continuously expanding the scope and efficacy of available treatments. Innovations span from advanced diagnostic tools that enable earlier and more accurate disease detection to the development of novel drug formulations and sophisticated regenerative therapies. These advancements allow veterinarians to offer more targeted and effective solutions for complex conditions, enhancing treatment outcomes and horse welfare. According to Boehringer Ingelheim's April 2024 announcement on its 2023 performance, the company's Research and Development investments increased by 14.2% to EUR 5.8 billion in 2023, underscoring significant industry commitment to therapeutic innovation across its animal health portfolio. Furthermore, the broader equine animal health sector demonstrates substantial economic activity, with Zoetis, a leading animal health company, generating revenue of $8.5 billion in 2023, as reported in its May 2024 press release.

Download Free Sample Report

Key Market Challenges

The persistent shortage of skilled equine veterinarians represents a significant impediment to the expansion of the Global Equine Veterinary Therapeutics Market. A limited number of practitioners directly restricts the accessibility of essential veterinary services, including routine health examinations, disease diagnosis, and the administration of critical pharmaceuticals and vaccines. This constraint means that even with advanced therapeutics available, their deployment to the substantial equine population is bottlenecked by the human resources required for delivery and oversight.

This shortage extends beyond new entrants into the profession. Existing practitioners face considerable workload pressures, further exacerbating the challenge. According to the 2024 AVMA AAEP Report on the Economic State of the Equine Veterinary Profession, 23% of equine associates and 12% of equine practice owners were considering or had decided to leave equine practice. Such high rates of potential attrition among experienced professionals directly reduce the capacity for delivering therapeutic treatments. This situation can lead to delayed or forgone veterinary care for horses, thereby limiting the sales volume and growth potential for specialized equine pharmaceuticals, vaccines, and diagnostic tools within the market.

Key Market Trends

Two significant trends shaping the Global Equine Veterinary Therapeutics Market are the shift towards personalized equine treatment plans and the rising integration of telemedicine and remote diagnostics.

The shift towards personalized equine treatment plans represents a critical evolution, moving beyond standardized protocols to cater to the individual physiological and genetic makeup of each horse. This approach leverages advanced diagnostics, including genetic testing, to inform targeted therapeutic interventions. A collaborative network of scientists in the equine industry, the S1094 United States Department of Agriculture Multistate Research Project, published a report in August 2025 detailing insights from a survey of 412 horse owners across 44 states. This study, a concerted industry effort to advance equine genomics, indicated a significant majority of respondents expressed strong interest in genetic testing to inform decisions regarding diversity and performance traits, directly demonstrating a market pull towards customized therapeutic strategies based on individual equine profiles.

The rising integration of telemedicine and remote diagnostics is similarly transforming equine healthcare delivery, enhancing accessibility and efficiency in veterinary services. This trend allows for continuous monitoring, timely interventions, and expert consultations regardless of geographical barriers, which is particularly beneficial for horses in rural equestrian areas. While specific numerical data on equine telemedicine adoption from an industrial association is not available, the broader veterinary industry is seeing considerable advancements in diagnostic technologies that support remote applications. For example, Zoetis announced in January 2024, the expansion of its Vetscan Imagyst platform to include AI Urine Sediment Analysis, representing an advancement in diagnostic capabilities that facilitates remote assessment and more efficient clinical decision-making for various animal health concerns.

Segmental Insights

The Anti-Inflammatory segment is a rapidly expanding key area within the Global Equine Veterinary Therapeutics Market. This accelerated growth primarily stems from the indispensable role these therapeutics play in managing prevalent equine health issues, including post-operative recovery, injury management, and various chronic conditions, particularly in high-value performance and racehorses. The segment's expansion is further driven by the increasing incidence of musculoskeletal problems and joint disorders in horses, necessitating effective pain relief and recovery solutions. Additionally, growing awareness among equine caretakers regarding early signs of discomfort, coupled with the rising popularity of equestrian sports and associated injury rates, significantly boosts demand for anti-inflammatory medications. This is supported by the consistent preference for these drugs due to their proven efficacy in enhancing mobility and overall quality of life for equines.

Regional Insights

North America dominates the global equine veterinary therapeutics market due to several distinct factors. The region benefits from a substantial equine population actively engaged in diverse equestrian sports, recreational activities, and agriculture, which inherently generates consistent demand for advanced veterinary care. This is further supported by a robust and sophisticated veterinary infrastructure, including specialized equine clinics and research institutions focused on health and performance. Additionally, high owner awareness and significant investment in equine well-being, coupled with well-established regulatory bodies like the Food and Drug Administration Center for Veterinary Medicine, promote innovation and the adoption of effective therapeutic solutions.

Recent Developments

• In September 2025, Animalcare Group PLC entered into an agreement with 272Bio Ltd to develop and commercialize a novel biological treatment for sweet itch in equines. This collaboration focuses on addressing a common condition affecting approximately 8% of horses globally, representing a significant annual addressable market estimated between EUR150 million and EUR200 million. The program is in its preclinical research phase, with an initial objective of achieving proof of concept over the next 18-24 months. This initiative reinforces Animalcare's strategy to expand its equine franchise and establish a pipeline of innovative products for the global equine veterinary therapeutics market.

• In July 2025, ElleVet Sciences introduced ElleVet Equine Pellets with CBD + CBDA, a new product designed for recreational horses. This launch marked an expansion of their clinically proven hemp formula to the equine community, aiming to support focus, stress, and mobility. Open-label studies conducted during the development of these pellets demonstrated approximately 70-90% improvement in movement and behavior over a four-week investigation. The product, which is National Animal Supplement Council (NASC) certified, reflects the company's commitment to delivering effective and trusted solutions for animal well-being in the global equine veterinary therapeutics market.

• In June 2025, bioMérieux launched VETFIRE™, a ready-to-use PCR kit significantly enhancing the testing process for equine infectious respiratory diseases. This new diagnostic tool provides highly accurate results within less than 20 minutes by leveraging advanced PCR technology. VETFIRE™ offers a comprehensive solution for the simultaneous detection of seven infectious respiratory pathogens in horses, enabling veterinarians to make rapid, informed decisions regarding treatment and management strategies. This breakthrough in diagnostics is crucial for managing equine health and mitigating the impact of respiratory disease outbreaks within the global equine veterinary therapeutics market.

• In February 2025, Aurora Pharmaceutical announced the availability of EquiCoxib, an FDA-approved generic equivalent for firocoxib. This non-steroidal anti-inflammatory drug (NSAID) is specifically indicated for the management of pain and inflammation associated with osteoarthritis in horses. EquiCoxib offers veterinarians and horse owners a cost-effective option for equine pain relief, providing a simple and effective solution that aims to maintain consistent pain management. This product is available by prescription through licensed veterinarians and contributes to the range of therapeutic options within the global equine veterinary therapeutics market.

Key Market Players

• Merck & Co., Inc.
• Thermo Fisher Scientific Inc (Affymetrix)
• Elanco Animal Health Inc.
• Zoetis Services LLC
• Farnam Companies, Inc.

Report Scope:

In this report, the Global Equine Veterinary Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Equine Veterinary Therapeutics Market, By Drugs:

o   Anti-Inflammatory

o   Anti-Infective

o   Parasiticides

o   Others

• Equine Veterinary Therapeutics Market, By Route of Administration:

o   Oral

o   Parental

o   Topical

• Equine Veterinary Therapeutics Market, By Distribution Channel:

o   Veterinary Hospital

o   Veterinary Clinics

o   Pharmacies and drugstores

o   E-commerce

o   Other

• Equine Veterinary Therapeutics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Equine Veterinary Therapeutics Market.

Available Customizations:

Global Equine Veterinary Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Equine Veterinary Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]